Stockscreener 앱 받기
39.15
4.14%
-1.69
시장 영업 전:
39.25
0.10
+0.26%
전일 마감가:
$40.84
열려 있는:
$40.615
하루 거래량:
981.66K
Relative Volume:
1.03
시가총액:
$2.78B
수익:
-
순이익/손실:
$-141.43M
주가수익비율:
-15.93
EPS:
-2.4581
순현금흐름:
$-226.41M
1주 성능:
-5.55%
1개월 성능:
-28.40%
6개월 성능:
+19.21%
1년 성능:
+47.18%
1일 변동 폭
$38.88
$40.75
1주일 범위
$38.88
$44.78
52주 변동 폭
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
39.15 | 2.90B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
425.00 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.10 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.31 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 40.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
317.00 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Canaccord Genuity | Buy |
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program - TipRanks
Structure Therapeutics (NASDAQ: GPCR) funds obesity drug push with $1.46B cash - Stock Titan
Obesity drug gains momentum as Structure (NASDAQ: GPCR) eyes Phase 3, boosts ATM - Stock Titan
Obesity pill developer posts 16.3% weight loss, targets Phase 3 - Stock Titan
GPCR (NASDAQ: GPCR) expands ATM program to $400M capacity - Stock Titan
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Structure Therapeutics Reports Weight Loss Success in Obesity Drug Trial - HarianBasis.co
Universal Beteiligungs und Servicegesellschaft mbH Buys 67,338 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Canaccord Genuity Group to Strong-Buy Rating - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 Summary - Quartr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Five obesity and diabetes studies from Structure Therapeutics head to ADA - Stock Titan
Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Pullback - Sahm
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
[ARS] Structure Therapeutics Inc. SEC Filing - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan
Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily
Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - Sahm
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
FMR LLC funds trim 17,452 Structure Therapeutics (GPCR) ADS holdings - Stock Titan
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill - TradingView
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results? - TradingView
Structure Therapeutics Appoints Matthew Lang as COO and General Counsel to Advance Obesity Drug Pipeline - Minichart
Structure Therapeutics stock rating maintained at Outperform by Leerink - Investing.com
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer - TipRanks
Structure Therapeutics (NASDAQ: GPCR) appoints Matthew Lang as COO and General Counsel - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Structure Therapeutics names Matthew Lang as COO and counsel - Investing.com
Metsera legal chief joins Structure as COO ahead of Phase 3 - Stock Titan
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Behavioral Patterns of GPCR and Institutional Flows - Stock Traders Daily
Why Structure Therapeutics Stock Is Suddenly Sinking - TipRanks
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics Stock Suddenly Took Off Today - TipRanks
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.87%
1.17%
자본화:
|
볼륨(24시간):